UK markets closed

MagForce AG (MGFRF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
3.85000.0000 (0.00%)
At close: 08:30AM EST
Full screen
Trade prices are not sourced from all markets
Previous close3.8500
Open3.8500
BidN/A x N/A
AskN/A x N/A
Day's range3.8500 - 3.8500
52-week range3.7800 - 6.0100
Volume300
Avg. volume4
Market cap113.431M
Beta (5Y monthly)2.43
PE ratio (TTM)6.86
EPS (TTM)0.5610
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    MagForce AG: Enrollment in Stage 2b of Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System successfully underway following IRB approval

    DGAP-News: MagForce AG / Key word(s): Study20.12.2021 / 08:30 The issuer is solely responsible for the content of this announcement.MagForce AG: Enrollment in Stage 2b of Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System successfully underway following IRB approval Stage 2b of the single arm study will enroll up to 100 men who have progressed to intermediate risk prostate cancer stage and are under active surveillance First patients enrolled; Patient

  • EQS Group

    Original-Research: MagForce AG (von GBC AG)

    Original-Research: MagForce AG - von GBC AG Einstufung von GBC AG zu MagForce AG Unternehmen: MagForce AG ISIN: DE000A0HGQF5 Anlass der Studie: Research Note Empfehlung: Buy Kursziel: 11.00 EUR Kursziel auf Sicht von: 31.12.2022 Letzte Ratingänderung: Analyst: Cosmin Filker, Marcel Goldmann 1st HY 2021: FDA approval for final pivotal study received, forecasts and price target confirmed, rating: BUY In the context of the research study (Anno) of 20.07.2021, we had already postulated our expectati

  • EQS Group

    MagForce AG Publishes Financial Results for H1/2021 and Operative Highlights

    DGAP-News: MagForce AG / Key word(s): Half Year Report28.10.2021 / 08:30 The issuer is solely responsible for the content of this announcement.MagForce AG Publishes Financial Results for H1/2021 and Operative Highlights- Europe: Significant upward trend - both in patient numbers and in the number of centers in Europe offering NanoTherm therapy- USA: Stage 2a of pivotal single-arm study for the focal ablation of intermediate risk prostate cancer successfully completed - Stage 2b with final protoc